Patients rate new skin disease treatment in groundbreaking saudi survey
NCT ID NCT06785779
Summary
This study surveys adults in Saudi Arabia with moderate to severe hidradenitis suppurativa (HS), a painful skin condition, who are starting a new treatment called secukinumab. Researchers will ask patients about their treatment satisfaction, pain levels, and quality of life over 24 weeks to understand their early experiences. The goal is to learn how patients feel about the convenience, safety, and effectiveness of this treatment in real-world clinical practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA (HS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGRiyadh, SAU, 11525, Saudi Arabia
-
Novartis Investigative Site
RECRUITINGJeddah, 21391, Saudi Arabia
-
Novartis Investigative Site
RECRUITINGJeddah, 23311, Saudi Arabia
-
Novartis Investigative Site
RECRUITINGRiyadh, 11211, Saudi Arabia
Conditions
Explore the condition pages connected to this study.